Argenx initiated with a Buy at Guggenheim. Guggenheim analyst Yatin Suneja initiated Argenx with a Buy rating and $157 price target, citing his view that efgartigimod, the company’s lead asset, offers a best and first-in-class profile with applicability across several autoimmune diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.